To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.

 
 

Description

This poster examines the relationship between clinical symptom scales and electroencephalographic (EEG) biomarkers in patients with Opioid Use Disorder (OUD). Participants from inpatient substance use treatment facilities completed validated mental health and withdrawal assessments, including the COWS, PHQ-9, HAM-A, and ASRS followed by cognitive testing while undergoing 19-lead EEG recording.

Preliminary findings indicate that synthetic opioid use is associated with prolonged P300 response latency across brain regions, suggesting measurable neurophysiologic differences tied to substance type and addiction severity. The study explores how EEG metrics may complement subjective symptom reporting to provide more objective markers of addiction status, co-morbid psychiatric burden, and recovery progress. Ongoing work aims to expand the dataset, improve statistical power, and identify additional EEG biomarkers relevant to treatment monitoring and clinical outcomes.

Disciplines

Medical Biochemistry | Medical Biophysics | Neurology | Neurosciences | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Other Chemicals and Drugs

Keywords

Opioid Use Disorder; OUD; Electroencephalography; EEG biomarkers; Addiction neuroscience; Substance use disorder; Synthetic opioids; P300 latency; Event-related potentials; Cognitive neuroscience; Mental health scales; Clinical symptom correlation; PHQ-9; HAM-A; ASRS; COWS; Withdrawal assessment; Neurophysiology; Brain electrophysiology; Portable EEG; WAVi headset; Oddball paradigm; Flanker test; Trail making test; Inpatient treatment; Recovery monitoring; Biomarker development; Psychiatric comorbidity; Depression; Anxiety; ADHD; Quantitative EEG; Addiction treatment outcomes

Document Type

Poster

Download

Share

COinS
 

Relationships Between Clinical Symptom Scales and EEG Biomarkers in OUD Patients

This poster examines the relationship between clinical symptom scales and electroencephalographic (EEG) biomarkers in patients with Opioid Use Disorder (OUD). Participants from inpatient substance use treatment facilities completed validated mental health and withdrawal assessments, including the COWS, PHQ-9, HAM-A, and ASRS followed by cognitive testing while undergoing 19-lead EEG recording.

Preliminary findings indicate that synthetic opioid use is associated with prolonged P300 response latency across brain regions, suggesting measurable neurophysiologic differences tied to substance type and addiction severity. The study explores how EEG metrics may complement subjective symptom reporting to provide more objective markers of addiction status, co-morbid psychiatric burden, and recovery progress. Ongoing work aims to expand the dataset, improve statistical power, and identify additional EEG biomarkers relevant to treatment monitoring and clinical outcomes.